Global Chemically Synthesized Alanyl-Glutamine Market Strategic Research Report

Scope of the Report

The global Chemically Synthesized Alanyl-Glutamine market size is predicted to grow from US$ 57.78 million in 2025 to US$ 84.22 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

In 2025, the global sales volume of chemically synthesized alanyl-glutamine reached 516 metric tons, with an average price of $108.9 per kilogram.

Chemically synthesized alanyl-glutamine (Ala-Gln) refers to a production method that utilizes organic synthesis techniques—such as protecting group strategies, condensation reactions, and deprotection steps—to specifically link L-alanine and L-glutamine (or L-glutamic acid) into a dipeptide. Chemical synthesis methods primarily include liquid-phase synthesis (SPS) and solid-phase peptide synthesis (SPPS), with liquid-phase synthesis serving as the mainstream route for industrial production. The core concept of this method involves introducing protecting groups (such as benzyloxycarbonyl/CBz or tert-butoxycarbonyl/Boc) to shield the α-amino or carboxyl groups of the amino acids and prevent side reactions; subsequently, a condensation agent (such as DCC or the hexachloroethane/triphenylphosphine system) catalyzes the formation of the peptide bond, followed by the removal of protecting groups to yield the final product.

The raw material system for chemically synthesized alanyl-glutamine comprises five major categories: amino acid raw materials, protecting group reagents, condensation agents, solvents and catalysts, and ammonolysis reagents. Amino acid raw materials represent the primary cost component, consisting mainly of L-alanine and L-glutamine (or L-glutamic acid as a substitute). Among these, L-glutamine—valued for its dual utility as a pharmaceutical raw material and a biochemical food ingredient—is in high demand with steadily rising prices, making it a key factor driving up synthesis costs; conversely, L-glutamic acid is relatively inexpensive and readily available, prompting some companies to develop new production routes using L-glutamic acid to reduce raw material costs. Protecting group reagents include di-tert-butyl dicarbonate (for Boc protection), benzyl chloroformate (for CBz protection), and phthalic anhydride; these are used for the temporary protection of amino acid functional groups and are characterized by high unit prices and significant consumption volumes. Condensing agents such as N,N'-dicyclohexylcarbodiimide (DCC), hexachloroethane, and triphenylphosphine are used to catalyze peptide bond formation; however, DCC is expensive, and the dicyclohexylurea (DCU) byproduct generated after the reaction is highly toxic and difficult to remove. Solvents and catalysts include organic solvents like tetrahydrofuran, dichloromethane, acetone, methanol, thionyl chloride, and trifluoroacetic acid (TFA), as well as catalysts for hydrogenation, such as palladium on carbon (Pd/C). Ammonolysis reagents—primarily concentrated aqueous ammonia or liquid ammonia—are used to convert acyl chloride or ester groups into amide groups.

Regarding the cost structure, raw materials typically account for 50%–70% of the total cost in chemical synthesis, with L-glutamine (or L-glutamic acid) and protecting group reagents representing the largest expenditures; chiral reagents (such as D-α-chloropropionyl chloride) are extremely expensive, severely constraining large-scale industrial production. Solvent and reagent costs account for approximately 15%–25%; large quantities of organic solvents are consumed, recovery costs are high, and certain solvents (e.g., dichloromethane, tetrahydrofuran) are toxic and volatile, resulting in high environmental treatment expenses. Equipment and energy costs make up about 10%–15%; chemical synthesis involves multi-step reactions, low-temperature control, vacuum concentration, and catalytic hydrogenation, placing high demands on equipment such as reaction vessels, distillation columns, and hydrogenation reactors, while also entailing significant energy consumption. Labor and environmental costs account for 5%–15%; the synthesis process involves numerous complex steps requiring highly skilled technical personnel, and the treatment of generated waste liquids, gases, and solids (such as DCU byproducts) is difficult and costly in terms of environmental compliance. Additionally, downstream purification costs (crystallization, recrystallization, column chromatography, etc.) constitute a significant portion of the total, as chemically synthesized products often contain impurities such as racemates and tripeptide or tetrapeptide byproducts, necessitating complex purification processes. Overall, although chemical synthesis methods feature mature processes and controllable reactions, their total production costs are significantly higher than those of fermentation or enzymatic methods. This is due to a reliance on chiral reagents and expensive protecting groups, complex multi-step procedures, low overall yields (typically 40–60%), and high costs associated with waste treatment; consequently, industrial production has increasingly shifted toward biosynthetic methods in recent years.

This report presents a comprehensive overview of the global Chemically Synthesized Alanyl-Glutamine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Liquid-Phase Synthesis (SPS)
• Solid-Phase Synthesis (SPPS)

Segment by Purity

• ≥95%
• ≥98%
• ≥99%

Segment by Protecting Group Types

• CBz (Carbobenzyloxy) Protection
• Boc (tert-Butyloxycarbonyl) Protection
• Phthaloyl Protection

Segment by Application

• Pharmaceuticals Industry
• Food & Beverages
• Sports Nutrition & Supplements
• Animal Feed
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Chemically Synthesized Alanyl-Glutamine market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceuticals Industry, Food & Beverages, Sports Nutrition & Supplements evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact